免疫检查点阻断通过扩增效应 CD8⁺ T 细胞克隆增强淋巴细胞清除性化疗诱导的抗肿瘤免疫
Immune Checkpoint Blockade Augments Lymphodepleting Chemotherapy-Induced Antitumor Immunity by Expanding Effector CD8+ T-cell Clones.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
黑色素瘤中的 TIL 临床经验：过去、现在与未来
英文原题：The Clinical TIL Experience in Melanoma: Past, Present, Future.
查看英文原题
The Clinical TIL Experience in Melanoma: Past, Present, Future.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
2024年2月美国食品药品监督管理局批准lifileucel，标志着采用TIL（肿瘤浸润淋巴细胞）过继细胞疗法治疗不可切除黑色素瘤30多年研究的顶峰。在这篇综述中，我们重点介绍TIL疗法治疗黑色素瘤的关键历史数据，以及目前为提高其疗效和适用性所做的努力。
展开英文摘要原文
The recent approval of lifileucel by the US Food and Drug Administration in February 2024 was the culmination of over 3 decades of research in adoptive cell therapy with tumor-infiltrating lymphocytes (TILs) for unresectable melanoma. In this review, we highlight key historical data for TIL therapy in melanoma as well as ongoing efforts to improve its efficacy and applicability.
论文信息
- 作者
- Smithy JW、Schoenfeld AJ、Betof Warner A
- 单位
- Memorial Sloan Kettering Cancer Center, New York, New York. Electronic address: smithyj@mskcc.org.United States
- 文献类型
- 综述
- 期刊
- Transplantation and cellular therapy2025 Mar
- 原文标识
- PubMed 40089331 · DOI 10.1016/j.jtct.2024.11.013